{"id":"W2597559961","doi":"10.1200/jco.2013.31.15_suppl.tps652","title":"A randomized, multicenter, double-blind phase III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(–) breast cancer who have not received any prior systemic anticancer treatment for advanced disease.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Palbociclib; Medicine; Letrozole; Internal medicine; Adverse effect; Oncology; Regimen; Progression-free survival; Neutropenia; Placebo; Clinical endpoint; Fulvestrant; Breast cancer; Phases of clinical research; Metastatic breast cancer; Clinical trial; Cancer; Tamoxifen; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004030381,0.003162807,0.003765602,0.0006836036,0.0008146876,0.001414813,0.001665531,0.002437032,0.008409514],"category_scores_gemma":[0.003247163,0.001426539,0.001983275,0.0006321577,0.002388417,0.001757441,0.0006987752,0.004657736,0.001735458],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00105093,"about_ca_system_score_gemma":0.002532631,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001032341,"about_ca_topic_score_gemma":0.00253216,"domain_scores_codex":[0.9987589,0.0007007467,0.00005647827,0.0002602156,0.00008470416,0.0001390371],"domain_scores_gemma":[0.998081,0.0004781399,0.000419629,0.0001866493,0.0001514242,0.0006831594],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9734662,0.01581134,0.0002880928,0.0002782206,0.0004269456,0.00001975592,0.00004013506,0.000241993,0.002936265,0.00007910034,0.0006307569,0.005781222],"study_design_scores_gemma":[0.951246,0.04743451,0.0003814638,0.00000893689,0.0001605028,0.00001321873,0.000009079807,0.0002035331,0.0002241306,0.00007511744,0.0002352796,0.000008248546],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9597103,0.003506053,0.002567158,0.001571157,0.001589426,0.02366495,0.003196891,0.0003802796,0.003813739],"genre_scores_gemma":[0.9492467,0.002974997,0.00669008,0.002921261,0.0009992965,0.02747813,0.002773051,0.00009600036,0.006820488],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008409514,"threshold_uncertainty_score":0.02813256,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1124280186970736,"score_gpt":0.4640249376706437,"score_spread":0.3515969189735701,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}